CD4 and inflammatory bowel disease: There is a clear unmet need for integrative studies that (i) profile the circulating miRNome, (ii) quantify key pro- and anti-inflammatory cytokines, and (iii) define CD4+ T-cell subset distributions in both the circulation and inflamed mucosa within a single, well-characterized, therapy-naïve IBD cohort.